M3 Biotechnology Inc. is the first company in the West to be singled out for recognition by the Science Coalition, an organization of the nation’s leading research universities dedicated to sustaining the federal government’s investment in basic scientific research.
Seattle-based M3, a company guided by president and CEO Leen Kawas that is commercializing a technology licensed out of Washington State University, is one of eight companies nationally that have been singled out to be featured on the website of the Science Coalition as part of its 20th anniversary.
The Science Coalition was formed in 1994 by a handful of universities with a singular goal of strengthening federal support for basic scientific and engineering research. Today, with some 60 public and private universities as members, the organization continues to work toward this goal by telling the stories of what federally funded university research has made possible.
SCIENCE 2034 is an initiative by The Science Coalition to mark its 20th anniversary by looking forward 20 years and focusing on the possibilities of the future. Selections was based on prediction on the next “Big Thing”, for which M3’s technology has been selected and featured.
The article for The Science Coalition’s SCIENCE 2034 website was co-authored by Leen Kawas, Ph.D, president and CEO of M3, and Joe Harding, Ph.D, co-inventor with Kawas of the MM201 drug.
Here is the key part of the article:
“By 2034, there will be an effective treatment for diseases like Parkinson’s and Alzheimer’s. This will represent a new class of regenerative drugs that restore lost function and prevent further deterioration – a significant departure from current treatments that aim simply to slow disease progression, not fix what’s broken.
Why do we think this enormous leap forward in medical science is possible when it’s only been 20 years since the concept of “regenerative medicine” was introduced as a targeted branch of medical science? Recent laboratory research has revealed a regenerative therapeutic pathway that holds the potential to reverse the course of neurodegenerative diseases.
The implications are enormous. Millions of Americans currently live with these debilitating and deadly diseases. The emotional and financial tolls are staggering. The medical costs associated with Alzheimer’s disease alone are estimated to be more than $200 billion a year.
The key to unlocking this medical future lies in the ability to control growth factor proteins in the body that orchestrate the development of the nervous system, guide changes in the brain associated with learning and memory formation, and, most critically, support repair and recovery when the nervous system is injured.
The activity of most growth factors is governed by a ‘switch’ which, when turned on, initiates cellular regeneration and, when turned off, inhibits cellular growth and induces cell death. These proteins just need to be revved up to accelerate and enhance their inherent regenerative capacity.”
“The Science Coalition’s recognition of M3 Biotechnology’s life-improving technology, discovered at and licensed from WSU, is further testimony to the quality of research and innovation coming from our institution,” said Anson Fatland, Associate Vice President of Economic Development and External Affairs. “M3 and the innovators who founded it, including Leen Kawas and Joe Harding, are a testament to the quality of work and entrepreneurship coming from WSU.”